Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Tactile Systems Technology (TCMD)
NASDAQ:TCMD
RESEARCH TOOLSreports
Holding TCMD?
Track your performance easily
Earnings Data
Report Date
Feb 25, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
0.32Last Year’s EPS
0.38Same Quarter Last Year
Moderate Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 05, 2018
|% Change Since: 15.16%
|Next Earnings Date:Aug 06, 2018
Earnings Call Sentiment|Neutral
The earnings call highlighted several positive developments, including revenue growth, improved gross margins, and strong cash flow, alongside strategic initiatives to mitigate Medicare-related challenges. However, the revenue results missed expectations, leading to a downward revision in full-year revenue guidance. While the implementation of new technologies and policy changes are seen as favorable, the impact of documentation requirements remains a challenge.Company Guidance
During Tactile Medical's Q3 2024 earnings call, the company provided guidance emphasizing key metrics and strategic initiatives. Total revenue for the quarter grew by 5% year-over-year to $73.1 million, with the lymphedema business contributing $65.3 million (a 4.4% increase) and airway clearance revenue reaching $7.8 million (a 10.3% increase). The gross margin improved by 410 basis points year-over-year, attributed to reduced material costs and warranty expenses. Adjusted EBITDA rose by 39.3% year-over-year, marking the 10th consecutive quarter of improvement, and cash and cash equivalents increased by $8.5 million to $82.1 million as of September 30, 2024. Despite these positive metrics, the company revised its full-year 2024 revenue guidance to a range of $292 million to $295 million, citing challenges such as increased Medicare documentation requirements impacting lymphedema sales and uneven DME buying patterns in the airway clearance segment. However, the adjusted EBITDA guidance was raised to $35 million to $37 million, reflecting robust profitability improvements. The company also highlighted its ongoing commercial initiatives, including technology investments, the launch of its next-generation lymphedema platform, and enhanced clinical evidence generation, which are expected to drive future growth and shareholder value.Revenue and Gross Margin Growth
Total revenue for Q3 increased by 5% year-over-year to $73.1 million. Gross margin increased by 410 basis points year-over-year due to lower material costs and warranty expenses.
Adjusted EBITDA Improvement
Adjusted EBITDA grew by 39.3% year-over-year, marking the 10th consecutive quarter of improvement, and the company raised its adjusted EBITDA guidance for 2024 to $35 million to $37 million.
Strong Cash Position
Cash and cash equivalents increased by $8.5 million sequentially, reaching $82.1 million as of September 30, 2024.
Growth in Airway Clearance Revenue
Airway clearance revenue increased by 10.3% year-over-year.
Positive Developments in Lymphedema Policy
CMS announced that the current LCD policy will be retired, and the NCD will be the sole coverage policy, which is seen as a positive change for patient access and business operations.
Introduction of Nimbl
The launch of Nimbl, a next-generation lymphedema platform, has been well-received with positive feedback from patients and clinicians.
---
TCMD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TCMD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 04, 2024 | $15.11 | $13.43 | -11.12% |
| Aug 05, 2024 | $11.54 | $13.14 | +13.86% |
| May 06, 2024 | $14.19 | $14.44 | +1.76% |
| Feb 20, 2024 | $14.67 | $14.20 | -3.20% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Tactile Systems Technology (TCMD) report earnings?
Tactile Systems Technology (TCMD) is schdueled to report earning on Feb 25, 2025, TBA Not Confirmed.
What is Tactile Systems Technology (TCMD) earnings time?
Tactile Systems Technology (TCMD) earnings time is at Feb 25, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TCMD EPS forecast?
TCMD EPS forecast for the fiscal quarter 2024 (Q4) is 0.32.
---